EP4153635A4 - Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same - Google Patents
Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same Download PDFInfo
- Publication number
- EP4153635A4 EP4153635A4 EP21809551.1A EP21809551A EP4153635A4 EP 4153635 A4 EP4153635 A4 EP 4153635A4 EP 21809551 A EP21809551 A EP 21809551A EP 4153635 A4 EP4153635 A4 EP 4153635A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- same
- antigen
- binding fragment
- her2 antibody
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/881,650 US11649294B2 (en) | 2017-11-14 | 2020-05-22 | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
PCT/KR2021/006361 WO2021235894A1 (en) | 2020-05-22 | 2021-05-21 | Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4153635A1 EP4153635A1 (en) | 2023-03-29 |
EP4153635A4 true EP4153635A4 (en) | 2024-06-26 |
Family
ID=78707650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21809551.1A Pending EP4153635A4 (en) | 2020-05-22 | 2021-05-21 | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4153635A4 (en) |
KR (1) | KR20230024911A (en) |
CA (1) | CA3184449A1 (en) |
IL (1) | IL298326A (en) |
WO (1) | WO2021235894A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017079694A2 (en) * | 2015-11-04 | 2017-05-11 | Priceman Saul J | Chimeric antigen receptors targeting her2 |
WO2020096646A1 (en) * | 2018-11-06 | 2020-05-14 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3824905A1 (en) * | 2012-08-20 | 2021-05-26 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
GB201518136D0 (en) * | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
-
2021
- 2021-05-21 EP EP21809551.1A patent/EP4153635A4/en active Pending
- 2021-05-21 WO PCT/KR2021/006361 patent/WO2021235894A1/en unknown
- 2021-05-21 IL IL298326A patent/IL298326A/en unknown
- 2021-05-21 CA CA3184449A patent/CA3184449A1/en active Pending
- 2021-05-21 KR KR1020227045034A patent/KR20230024911A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017079694A2 (en) * | 2015-11-04 | 2017-05-11 | Priceman Saul J | Chimeric antigen receptors targeting her2 |
WO2020096646A1 (en) * | 2018-11-06 | 2020-05-14 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells |
Non-Patent Citations (7)
Title |
---|
CONGCONG ZHANG: "ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 108, no. 5, 6 December 2015 (2015-12-06), GB, XP093160504, ISSN: 0027-8874, DOI: 10.1093/jnci/djv375 * |
DANIEL ABATE-DAGA ET AL: "CAR models: next-generation CAR modifications for enhanced T-cell function", MOLECULAR THERAPY - ONCOLYTICS, vol. 3, 1 January 2016 (2016-01-01), pages 16014, XP055564170, ISSN: 2372-7705, DOI: 10.1038/mto.2016.14 * |
KRUSCHINSKI ANNA ET AL: "Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 45, 11 November 2008 (2008-11-11), pages 17481 - 17486, XP055911709, ISSN: 0027-8424, DOI: 10.1073/pnas.0804788105 * |
KURT SCHÖNFELD ET AL: "Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor", MOLECULAR THERAPY, vol. 23, no. 2, 6 November 2014 (2014-11-06), US, pages 330 - 338, XP055265087, ISSN: 1525-0016, DOI: 10.1038/mt.2014.219 * |
SARWISH RAFIQ: "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 17, no. 3, 1 March 2020 (2020-03-01), NY, US, pages 147 - 167, XP093155916, ISSN: 1759-4774, Retrieved from the Internet <URL:https://www.nature.com/articles/s41571-019-0297-y.pdf> DOI: 10.1038/s41571-019-0297-y * |
See also references of WO2021235894A1 * |
XIANQIANG LIU ET AL: "Driving better and safer HER2-specific CARs for cancer therapy", ONCOTARGET, vol. 8, no. 37, 5 September 2017 (2017-09-05), pages 62730 - 62741, XP055546086, DOI: 10.18632/oncotarget.17528 * |
Also Published As
Publication number | Publication date |
---|---|
EP4153635A1 (en) | 2023-03-29 |
CA3184449A1 (en) | 2021-11-25 |
IL298326A (en) | 2023-01-01 |
KR20230024911A (en) | 2023-02-21 |
WO2021235894A1 (en) | 2021-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3712178A4 (en) | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same | |
EP3868783A4 (en) | Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same | |
EP4010378A4 (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
EP3882268A4 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
EP3901175A4 (en) | Anti-cd73 monoclonal antibody and application thereof | |
EP4079766A4 (en) | Chimeric antigen receptor for recognizing fc fragment and application thereof | |
EP3919512A4 (en) | HUMANIZED ANTI-Abeta MONOCLONAL ANTIBODY AND APPLICATION THEREOF | |
EP3922647A4 (en) | Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
EP4049684A4 (en) | Ri-labeled humanized antibody | |
EP3825333A4 (en) | Low functional adcc/cdc monoclonal antibody, preparation method therefor and use thereof | |
EP4043490A4 (en) | Humanized anti-vegf fab antibody fragment and use thereof | |
IL307417A (en) | Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same | |
EP3889180A4 (en) | Humanized anti-human ox40 monoclonal antibody, preparation method therefor and use thereof | |
EP3901171A4 (en) | Anti-human tim-3 monoclonal antibody and application thereof | |
EP3730519A4 (en) | Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof | |
EP4001306A4 (en) | Humanized anti-vegf monoclonal antibody | |
EP3955925A4 (en) | Humanized anti-pd-l1 antibodies | |
EP3988564A4 (en) | Leptin immunogen, hybridoma cell, monoclonal antibody, polyclonal antibody and use thereof | |
IL313187A (en) | Anti-tslp monoclonal antibody, antigen-binding fragment thereof and use thereof | |
EP3778637A4 (en) | Monoclonal antibody specifically reacting with dupan-2 antigen and method for producing same | |
EP3819311A4 (en) | Anti-abeta antibody, antigen-binding fragment thereof and application thereof | |
EP4153635A4 (en) | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same | |
EP4119578A4 (en) | Bcma-specific antibody and chimeric antigen receptor | |
EP4238991A4 (en) | Anti-tigit antibody or antigen-binding fragment thereof | |
EP3858855A4 (en) | Humanized anti-human ctla4 monoclonal antibody, preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GC CELL CORPORATION |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240529 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/705 20060101ALI20240523BHEP Ipc: C12N 5/0783 20100101ALI20240523BHEP Ipc: A61K 38/17 20060101ALI20240523BHEP Ipc: A61P 35/00 20060101ALI20240523BHEP Ipc: C07K 16/32 20060101AFI20240523BHEP |